股票简称：阳谷华泰 股票代码：300121 股票上市地：深圳证券交易所 债券简称：阳谷转债 债券代码：123211 债券上市地：深圳证券交易所 山东阳谷华泰化工股份有限公司 发行股份及支付现金购买资产 并募集配套资金暨关联交易报告书（草案） 摘要 （修订稿） 项目 交易对方 发行股份及支付现金 海南聚芯、王传华、武凤云、阳谷霖阳、阳谷泽阳、惠鲁睿高、聊 购买资产 城昌润、睿高致远、刘保乐 配套募集资金 不超过 35 名符合中国证监会规定的特定投资者 独立财务顾问 二〇二五年八月 阳谷华泰 发行股份及支付现金购买资产并募集配套资金暨关联交易报告书（草案）摘要 上市公司声明 本公司及全体董事、监事、高级管理人员保证重组报告书及其摘要内容不存 在虚假记载、误导性陈述或者重大遗漏，并对其真实性、准确性和完整性承担个 别和连带的法律责任。 本公司控股股东、实际控制人以及全体董事、监事、高级管理人员承诺：如 在本次交易过程中所披露或提供的信息涉嫌虚假记载、误导性陈述或者重大遗 漏，被司法机关立案侦查或者被中国证监会立案调查的，在形成调查结论以前不 转让在上市公司拥有权益的股份，并于收到立案稽查通知的两个交易日内将暂停 转 ...

Core Viewpoint - Yanggu Huatai's restructuring plan has been suspended due to the need for adjustments in the transaction scheme, as announced on August 2 [1] Group 1: Restructuring Details - The restructuring plan involves the acquisition of 100% equity of Bomi Technology for a total price of 1.443 billion yuan, with cash consideration of 433 million yuan and share consideration of 1.01 billion yuan [1][2] - Bomi Technology is primarily engaged in the research, production, and sales of high-performance polyimide materials, which are used in power semiconductor devices and advanced semiconductor packaging [2] - Yanggu Huatai aims to expand its business into the electronic chemical products sector, which is critical for semiconductor manufacturing, while maintaining its leading position in the rubber additive sector [3] Group 2: Financial Performance - Bomi Technology reported revenues of 32.795 million yuan and 33.949 million yuan for 2023 and 2024, respectively, with net losses of 11.7165 million yuan and 9.1819 million yuan [2] - The valuation of Bomi Technology shows a significant increase, with a 1330.32% appreciation based on a net asset value of 1.01 billion yuan as of December 31, 2024 [2] Group 3: Regulatory Process - The Shenzhen Stock Exchange raised nine major questions regarding the transaction, including the necessity and compliance of the cross-industry acquisition and the fairness of related party transaction pricing [2] - Yanggu Huatai has responded to the inquiries and is working on further modifications and supplements as requested by the exchange [3]